Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim

Criteria

Inclusion Criteria:

• Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH)

• Patients with symptoms, that according to physician require medical treatment to improve quality of life

• Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment

Exclusion Criteria:

• Patients with known hypersensitivity to Tamsulosin, or any other component of the product

• Patients with a history of orthostatic hypotension or severe liver failure